Business Context and Reporting Period
Pharvaris N.V., a foreign private issuer incorporated in the Netherlands, filed this Form 6-K on May 11, 2026. The filing reports the closing of an underwritten public offering of ordinary shares that commenced on May 8, 2026.
Key Financial Metrics
- Offering Size: 4,455,863 ordinary shares (including the full exercise of the underwriters' option to purchase an additional 581,199 shares).
- Offering Price: $29.68 per share.
- Net Proceeds: Approximately $124 million after deducting underwriting discounts and commissions.
- Revenue, Profit, and Cash Flow: The filing text does not provide specific values for revenue, profit, operating cash flow, margins, or debt levels.
Material Changes
The primary material event is the successful completion of the equity offering, resulting in a significant increase in the company's cash liquidity. The filing does not provide comparative financial data against prior periods to quantify changes in operating metrics.
Guidance, Outlook, and Use of Proceeds
Management intends to utilize the net proceeds primarily for the following purposes:
- Funding research and development expenses for late-stage clinical programs.
- Expanding the sales and marketing team in the U.S.
- Covering related commercialization expenses.
- Providing working capital and general corporate purposes.
The filing does not contain specific forward-looking financial guidance, risk factors, or contingencies beyond the standard incorporation of the Underwriting Agreement.
Investor Verification Checklist
- Verify the final number of shares issued and the exact net proceeds received after all transaction costs.
- Review the Underwriting Agreement (Exhibit 1.1) for lock-up periods, indemnification clauses, and underwriting discounts.
- Confirm the specific late-stage clinical programs designated for funding with the new capital.
- Assess the dilution impact of the 4,455,863 new shares on existing shareholders.